“current wound care plans, are basically clean dress wound weekly depending on the severity of the wound”
From my understanding this the biggest reason why diabetic wounds are so lethal - it’s difficult to get good, consistent care. The CEO referred to this in a recent panel he was on (I don’t have the link sorry) and basically said the control arm in the trial were doing better than anticipated, because they were seeing a specialist twice a week for a month then weekly/bi-weekly thereafter. From this, if the results demonstrate CYP-006TK is more effective than the ‘standard of care’ in this trial, then it would be multiples better than the standard of care incurred in the real world.
Also, I like how this quarterly breaks down the operations into the different delivery methods Cynata offer in present, clinical trials. I might be getting high on Hopium, but maybe that’s a sign of how a forthcoming license will be treated.
CYP Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)